BLOOD CHEMICAL CHANGES IN EXPERIMENTAL STREPTOCOCCUS SEPTICEMIA.

J Exp Med

Department of Bacteriology, College of Physicians and Surgeons, Columbia University, New York.

Published: July 1931

The following changes have been found to occur in rabbits given fatal intravenous doses of Streptococcus hemolyticus: The blood sugar concentration drops at a constant rate throughout the disease, but does not reach a condition of hypoglycemia. Glycogen is present in the liver at death. The CO(2) capacity is lowered markedly at first, then returns to a somewhat higher level, at which it continues until the terminal stage of the disease, when the acidosis becomes very marked. Inorganic phosphorus is markedly increased in concentration at the terminus of the disease. This increase is greater in animals showing an acute course than in those in which the disease is of the fulminating type. Calcium also shows terminal changes, decreases occurring in both groups. In the acutely infected rabbits the decrease is less than in the fulminating group, although in both a pathological level is reached. Non-protein nitrogen and creatinine are greatly increased in the terminal stages, in both groups of animals. It is suggested that these observations can be explained on the assumption of a large amount of acid production by the streptococcus in vivo.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2131953PMC
http://dx.doi.org/10.1084/jem.54.2.223DOI Listing

Publication Analysis

Top Keywords

blood chemical
4
chemical changes
4
changes experimental
4
experimental streptococcus
4
streptococcus septicemia
4
septicemia changes
4
changes occur
4
occur rabbits
4
rabbits fatal
4
fatal intravenous
4

Similar Publications

A cost-effective strategy is reported utilizing ionic liquid (IL), 1-hexyl-3-methylimidazolium bisulfate ([HMIM] HSO), to delaminate TiC MXene, thereby enhancing its efficiency in electrocatalyzing tryptophan (Trp) oxidation. The positively charged IL effectively intercalates within the negatively charged MXene layers, fostering structural stability through π-π stacking and electrostatic interactions. Consequently, the resulting IL-TiC composite not only maintained the inherent electronic conductivity of TiC but also significantly augmented its electrocatalytic prowess.

View Article and Find Full Text PDF

An aptamer-based electrochemical sensor for the quantification of the malaria biomarker lactate dehydrogenase.

Biosens Bioelectron

January 2025

Barcelona Institute for Global Health (ISGlobal), Barcelona, 08036, Spain; INTERFIBIO Research Group, Departament d'Enginyeria Química, Universitat Rovira i Virgili, Tarragona, 43007, Spain. Electronic address:

Malaria is one of the most deadly infectious diseases, causing the death of hundreds of thousands of patients each year. Global efforts to combat malaria necessitate the implementation of novel rapid diagnostic tests deployable at the point of care. Here, we present the development of an electrochemical aptamer-based (EAB) sensor for the quantification of the malaria biomarker Plasmodium falciparum lactate dehydrogenase (PfLDH).

View Article and Find Full Text PDF

Introduction: The contribution of obesity phenotypes to dyslipidaemia in middle-aged adults from four sub-Saharan African (SSA) countries at different stages of the epidemiological transition has not been reported. We characterized lipid levels and investigated their relation with the growing burden of obesity in SSA countries.

Methods: A cross-sectional study was conducted in Burkina Faso, Ghana, Kenya and South Africa.

View Article and Find Full Text PDF

Background: Exposure to ionizing radiation is inevitable due to its extensive use in industrial and medical applications. The search for effective and safe natural therapeutic agents as alternatives to chemical drugs is crucial to mitigate their side effects. This study aimed to evaluate the effects of citicoline as a standalone treatment or in combination with the anti-hepatotoxic drug silymarin in protecting against liver injury caused by γ-radiation in rats.

View Article and Find Full Text PDF

Alpelisib is a phosphatidylinositol 3-kinase inhibitor approved by the US Food and Drug Administration for the treatment of hormone receptor-positive metastatic breast cancer with (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) mutation. In recent years a number of adverse effects have been observed to be associated with this therapy, the most notable of which is hyperglycemia. A literature search was conducted to include case studies, case series, systematic reviews, and meta-analyses within the last 10 years that evaluated patients with mutated hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!